BridgeBio and Amgen Entered into a Non-Exclusive Clinical Collaboration for BBP-398 in P-I/II Study for Advanced Solid Tumors
Shots:
- The study will evaluate BBP-398 in combination with Lumakras including a dose-escalation period which will be followed by dose expansion and optimization. BridgeBio will be sponsoring the study and Amgen will provide a global supply of Lumakras
- BridgeBio is advancing its P-I clinical trial of BBP-398 in patients with solid tumors with the KRAS G12C mutation. This program is a part of company’s precision oncology pipeline and one of the 14 programs being advanced in the clinic or commercial setting
- BBP-398 is a small-molecular inhibitor of SHP2 which is a protein-tyrosine phosphatase that links growth factor, cytokine, and integrin signaling with the downstream RAS/ERK MAPK pathway for regulating cellular proliferation and survival
Ref: Bridgebio | Image: PR Newswire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com